Natalizumab for induction of remission in Crohn's disease

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 8, 2018, Pages

  Nelson, Seana M L ^a   Nguyen, Tran M ^b   Mcdonald, John W D ^b   Macdonald, John K ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; NATALIZUMAB; PLACEBO; ALPHA4 INTEGRIN; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR; INFLIXIMAB; INTEGRIN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; REMISSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING; ANTAGONISTS AND INHIBITORS; INDUCTION CHEMOTHERAPY; PATIENT DROPOUT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; INTEGRIN ALPHA4; INTEGRINS; NATALIZUMAB; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 85050721427     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006097.pub3     Document Type: Review

References (70)

1. Ghosh S. Alpha4 Integrin blockade in inflammatory bowel disease. Annals of the Rheumatic Diseases 2003;62(Suppl. 2):70-7. 8953766
2. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn's disease. New England Journal of Medicine 2003;348(1):24-32. 8953765
3. Rutgeerts P, Donoghue S, Palmer T. Quality of life improvements in a phase 2 study of natalizumab for active Crohn's disease. Gastroenterology 2003;124(4 Suppl. 1):A378. 8953767
4. The Antegren Publication Committee, Letchworth United Kingdom. A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to α4 integrin (AntegrenTM) in moderate to severely active Crohn's disease. Gastroenterology 2001;120(5 Suppl. 1):A-127-8. 8953768
5. Gordon FH, Lai CW, Hamilton MI, Allison MC, Fouweather M, Donoghue S, et al. Randomised double blind placebo controlled trial of recombinant humanised antibody to a4 integrin (AntegrenTM) in active Crohn's disease. Gastroenterology 1999;116(4 Part 2):A726. 8953770
6. Gordon FH, Lai CW, Hamilton MI, Allison MC, Fouweather M, Donoghue S, et al. Randomised double-blind placebo-controlled trial of recombinant humanised antibody to alpha-4 integrin (antegren) in active Crohns disease. Gut 1999;44:A42. 8953771
7. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121(2):268-74. 8953772
8. Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, Panaccione R, et al. 12-Month steroid-sparing results of natalizumab in a controlled study of patients with Crohn's Disease. Gastroenterology 2005;128(4 Suppl. 2):A576. 8953774
9. Colombel JF, Bornstein J, Hernandez C, Wolf D. Natalizumab provides consistent induction efficacy for patients with moderate to severe Crohn's Disease and elevated C-reactive protein a comparison of ENACT-1 and ENCORE. UEGW Abstract Database 2007. 8953775
10. Enns R, Colombel J, Feagan B, Hanauer S, Lawrance I, Panaccione R, et al. Safety, tolerability and immunogenicity of natalizumab in a phase III study of active Crohn's disease therapy (ENACT-1). Gastroenterology 2004;126(4 Suppl. 2):A462. 8953776
11. Feagan B, Colombel J, Enns R, Hanauer S, Lawrance I, Panaccione R, et al. Maintenance treatment with natalizumab improves the health related quality of life (HRQOL) in Crohn's disease patients. Gastroenterology 2006;130(4 Suppl 2):A-485. 8953777
12. Feagan BG, Panaccione R, Hass S, Panjabi S. The impact of natalizumab on the quality of life of patients exposed to or failing anti-TNFá therapy in the ENACT-2 trial. Gastroenterology 2009;136(Suppl. 1):S1059. 8953778
13. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. American Journal of Gastroenterology 2007;102(12):2737-46. 8953779
14. Geboes K, Allison MC, Cortot A, D'Haens G, Dahlerup JF, Hebuterne X, et al. Natalizumab decreases inflammatory cells within the colonic lamina propria of patients with active Crohn's disease: Results from ENACT-1. Gastroenterology 2004;126(a Suppl. 2):A213. 8953780
15. Lawrance I, Colombel J, Enns R, Feagan B, Hanauer S, Panaccione R, et al. Pharmacodynamic results from a phase 3 study evaluating natalizumab therapy of active Crohn's disease (ENACT-1). Gastroenterology 2004;126(4 Suppl. 2):A211. 8953781
16. Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Comparability of natalizumab pharmacokinetics (PK), alpha-4-integrin receptor saturation and clinical response in patients with Crohn's disease (CD) treated once monthly IV with either a fixed dose of 300 mg (ENACT-1) or doses of 3 or 6 mg/kg. Gastroenterology 2004;126(4 Suppl. 2):A76. 8953782
17. Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Efficacy Of natalizumab in patients with Crohn's disease and prior history of infliximab therapy: 12-month results from Enact-2. Gastroenterology 2005;128(4 Suppl 2):A584. 8953783
18. Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. Inflammatory Bowel Diseases 2008;14:S10. 8953784
19. Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Natalizumab maintains remission in patients with moderately to severely active Crohn's disease for up to 2-Years: Results from an open-label extension study. Gastroenterology 2006;130(4 Suppl 2):A-111. 8953785
20. Rutgeerts P, Allison MC, Cortot A, D'Haens G, Dahlerup JF, Hebuterne X, et al. Effects of natalizumab on gut healing in a phase 3 study of active Crohn's disease therapy (ENACT-1). Gastroenterology 2004;126(4 Suppl 2):A208. 8953786
21. Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Efficacy of assessment of Natalizumab in patients with Crohn's Disease and prior history of anti-TNF therapy: Results from ENACT. 2004 Gastroenterology;126(4 Suppl. 2):A76. 8953787
22. Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Efficacy of natalizumab in maintaining clinical response and remission in Crohn's disease: Comparison of sustained response and remission rates through 12 months Vs point-In-time response and remission rates at month 12. Gastroenterology 2005;128(4 Suppl. 2):A586. 8953788
23. Sandborn W, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Maintenance therapy with natalizumab does not require use of concomitant immunosuppressants for sustained efficacy in patients with active Crohn's Disease: Results from the ENACT-2 study. Gastroenterology 2006;130(4 Suppl. 2):A-482. 8953789
24. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance I, et al. Natalizumab induction and maintenance therapy for Crohn's disease. New England Journal of Medicine 2005;353(18):1912-25. 8953790
25. Schreiber S, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Immunogenicity of natalizumab in Crohn's patients following continuous or interrupted dosing. UEGW Abstract Database 2006. 8953791
26. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflammatory Bowel Diseases 2007;13(1):2-11. 8953793
27. Sands BE, Kozarek RA, Spainhour J, Barish C, Becker S, Goldberg LS, et al. Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease. Gastroenterology 2004;126(4 Suppl. 2):A463. 8953794
28. Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of Crohn disease patients after receiving natalizumab therapy. Gastroenterology Nursing 2009;32(5):327-39. 8953796
29. Feagan B, Fedorak R, Lashner B, Panaccione R, Present D, Raedler A, et al. Natalizumab induction therapy results in improved quality of life in Crohn's disease patients. UEGW Abstract Database 2006. 8953797
30. Lashner B, Feagan B, Fedorak R, Panaccione R, Present D, Spehlmann ME, et al. Natlizumab does not require the concomitant use of immunosuppressants for the induction of sustained response and remission in Crohn's disease patients. Gastroenterology 2007;132(4 Suppl. 1):A-507. 8953798
31. Panaccione R, Feagan B, Fedorak R, Lashner B, Present D, Rutgeerts P, et al. Natalizumab induces sustained response and remission in patients with Crohn's disease activity index scores .330: Results from the ENCORE trial. Gastroenterology 2007;132(4 Suppl. 1):A-508-9. 8953799
32. Panaccione R, Feagan B, Fedorak R, Lashner B, Present D, Rutgeerts P, et al. Natalizumab induces sustained response and remission in patients with Crohn's disease activity index scores 330: Results from the ENCORE trial. UEGW Abstract Database 2007. 8953800
33. Panaccione R, Feagan BG, Hass S, Panjabi S. The impact of natalizumab on the quality of life of patients exposed to or failing anti-TNFalpha therapy in the ENCORE trial. Gastroenterology 2009;136(5):A180. 8953801
34. Present D, Feagan B, Fedorak R, Lashner B, Panaccione R, Rutgeerts P, et al. Natalizumab induces sustained response and remission in Crohn's patients after previous infliximab failure: Results from the Encore trial. Gatsroenterology 2007;132(4 Suppl. 1):A 507. 8953802
35. Rutgeerts P, Feagan B, Fedorak R, Lashner B, Panaccione R, Present D, et al. Natalizumab induces sustained response and remission in Crohn's disease patients after previous anti-TNF alpha therapy failure: results from the ENCORE trial. UEGW- Abstract Database 2007. 8953803
36. Spehlmann M, Feagan B, Fedorak R, Lashner B, Panaccione R, Present D, et al. Natalizumab does not require the concomitant use of immunosuppressants for the induction or sustained response and remission in Crohn's disease patients. UEGW - Abstract Database 2007. 8953804
37. Spehlmann M, Feagan B, Fedorak R, Lashner B, Panaccione R, Present D, et al. Natalizumab induces sustained response and remission in patients with active Crohn's disease: ENCORE trial results. UEGW Abstract Database 2006. 8953805
38. Targan S, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Maintenance therapy with natalizumab (enact-2) for patients with active Crohn's disease despite immunosuppressant use. Gastroenterology 2005;128(4 Suppl 2):A587. 8953806
39. Targan SR, Feagan B, Fedorak R, Lashner B, Panacionne R, Present D, et al. Natalizumab induces sustained response and remission with active Crohn's disease: results from the ENCORE trial. Gastroenterology 2006;130(4 Suppl 2):A108. 8953807
40. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 2007;132(5):1672-83. 8953808
41. Wolf D, Feagan B, Fedorak R, Lashner B, Panaccione R, Present D, et al. Natalizumab is effective without the concomitant use of immunosuppressants or corticosteroids for the induction and maintenance of response and remission in patients with Crohn's disease. Inflammatory Bowel Disease 2008;14(S1):S30. 8953809
42. Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflammatory Bowel Diseases 2012;18(12):2203-08. 8953811
43. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. New England Journal of Medicine 2005;353(4):432-3.
44. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. New England Journal of Medicine 2003;348(1):68-72.
45. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. New England Journal of Medicine 2005;353(4):414-6.
46. Biogen. TYSABRI® (natalizumab): PML in patients receiving TYSABRI (USA TYSABRI PML Update). medinfo.biogen.com/ (accessed 30 June 2017).
47. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine 2016;366(20):1870-80.
48. Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV Jr. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases 2015;21(7):1695-708.
49. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. New England Journal of Medicine 2009;361(11):1067-74.
50. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016;66:839-51.
51. Ge WS, Fan JG. Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis. World journal of gastroenterology 2015;21(15):4744-9.
52. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
53. Hesterberg PE, Winsor-Hines D, Briskin MJ, Solar-Ferran D, Merrill C, Mackay CR, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111(5):1373-80.
54. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
55. Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. New England Journal of Medicine 2005;353(4):369-74.
56. Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. New England Journal of Medicine 2005;353(4):375-81.
57. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
58. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. American Journal of Gastroenterology 2009;104(2):465-83.
59. Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine 2015;94(10):e556.
60. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17.
61. Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. Journal of Clinical Investigation 1993;92(1):372-80.
62. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine 2013;369(8):711-21.
63. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, Available from www.cochrane-handbook.org, 2011.
64. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. Journal of Pharmacology and Experimental Therapeutics 2009;330(3):864-75.
65. Thoreson R, Cullen JJ. Pathophysiology of inflammatory bowel disease: an overview. Surgical Clinics of North America 2007;87(3):575-85.
66. Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn's disease. World Journal of Gastroenterology 2012;18(2):105-18.
67. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. New England Journal of Medicine 2005;353(4):362-8.
68. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England Journal of Medicine 2006;354(9):924-33.
69. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006097]
70. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006097.pub2]